Scholarlink

Introduction <p>Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (&lt; 60 vs. ≥ 60&#xa0;years) in postmenopausal women and identified associated risk factors.</p> Materials and Methods <p>We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.</p> Results <p>Among 306 postmenopausal women, 173 were &lt; 60&#xa0;years (group 1) and 133 were ≥ 60&#xa0;years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60&#xa0;years (30.1% vs. 16.8%, <i>p</i> = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60&#xa0;years (OR = 2.34, 95% CI: 1.19–4.61), active smoking (OR = 2.98, 95% CI: 1.27–7.02), reduced appendicular lean mass index (ALMI &lt; 5.5&#xa0;kg/m<sup>2</sup>; OR = 3.72, 95% CI: 1.78–7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05–1.25 per 10&#xa0;ng/mL increase).</p> Conclusion <p>Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60&#xa0;years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月31日

查看全文
  • Line Abdulghani,
  • Hélène Verkindt,
  • Laurine Cadart,
  • Cécile Philippoteaux,
  • Robert Caiazzo,
  • Julien Paccou

摘要

Introduction

Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (< 60 vs. ≥ 60 years) in postmenopausal women and identified associated risk factors.

Materials and Methods

We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.

Results

Among 306 postmenopausal women, 173 were < 60 years (group 1) and 133 were ≥ 60 years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60 years (30.1% vs. 16.8%, p = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60 years (OR = 2.34, 95% CI: 1.19–4.61), active smoking (OR = 2.98, 95% CI: 1.27–7.02), reduced appendicular lean mass index (ALMI < 5.5 kg/m2; OR = 3.72, 95% CI: 1.78–7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05–1.25 per 10 ng/mL increase).

Conclusion

Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.